Search

Adresse: http://www.studienurologie.de/referenzen/publizierte-poster-der-studienpraxis/ Treffer-Übereinstimmung: 0,39

Prostatakarzinom

• Hochrisiko M0 PCa (im Anschluss an radikale Prostatektomie): 
  • Phase II Studie ADAM: Apalutamid adjuvant vs. Standard of Care

• Neu diagnostiziertes M1 PCa (hormonsensitiv)
  • Phase III Capitello Studie: Capivasertib + Abiraterone Versus Plazebo + Abiraterone beim De Novo mHSPC mit PTEN Verlust
  • Abirateron plus Niraparib versus Abirateron + Plazebo (bei Vorhandensein einer DNA-Reparaturgen-Mutation, wird im Rahmen der Studie getestet)
  • Enzalutamid + Talazoparib versus Enzalutamid + Plazebo (bei Vorhandensein einer DNA-Reparaturgen-Mutation, wird im Rahmen der Studie getestet
  • Abiraterone + Abemaciclib vs. Abiraterone plus Placebo bei Hochrisiko metastasiertem Prostatakarzinom

• mCRPC (noch keine vorherige Behandlung mit neuer hormoneller Therapie
  • HC-1119 (neues Antiandrogen) versus Enzalutamid

• mCRPC (Progress nach Abiraterone/Enzalutamid/Apalutamid/Darolutamid)
  • Cabozantinib + Atezolizumab vs. Abiraterone/Enzalutamid
  • Nivolumab + Docetaxel vs. Placebo + Docetaxel

• mCRPC (Progress nach Docetaxel und Abiraterone/Enzalutamid/Apalutamid/Darolutamid)
  • Tyrosinkinaseinhibitor XL-092 als Monotherapie oder in Kombination mit Atezolizumab

• Neuroendokrines Prostatakarzinom

  • Pembrolizumab + Lenvatinib oder Pembrolizumab + Vibostolimab (Immuntherapie), Alternativ:Pembrolizumab + Platinhaltige Chemotherapie

Adresse: http://www.studienurologie.de/klinische-studien/therapieansatz-in-klinischen-studien-bei-prostatakrebs/ Treffer-Übereinstimmung: 0,03

Die Studienpraxis Urologie partizipiert in allen aktuellen, zentralen, klinischen Phase II, III und IV -Studien zur medikamentösen Behandlung des Prostatakarzinoms und darf auf eine Erfolgsgeschichte abgeschlossener Trials als einer der internationalen Top-Recruiter verweisen

• PARP-Inhibitor Olaparib, open-label bei Vorliegen einer BRCA Mutation versus Abiraterone / Enzalutamid entsprechend ärztlicher Entscheidung, PROFOUND, Phase III

  8th top recruiter in world, 1st in Germany

• Randomized study of ODM-201 in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer, ARASENS, 17777, Phase III, EudraCT No 2015–002590–38

  Top recruiter in Germany

• Randomized double-blind study with ARN-509 in men with non-metastatic castration - resistant prostate cancer, SPARTAN, ARN-509-003, phase III, EudraCT No 2012-004322-24

  Top recruiter in Germany

• Randomized, double-blind, comparative study of Abiraterone Acetata plus Prednisone plus androgen deprivation therapy (ADT) verus ADT alone in newly diagnosed subjects with high-risk, metastatic hormone-naive prostate cancer (mHNPC), LATITUDE, phase III, EudraCT: 2012-002940-26 33

  Top recruiter in Germany

• Randomized double-blind study with DCVAC/PCa in men with metastatic hormonrefractory prostate cancer eligible for 1^st line chemotherapy, VIABLE, SP005, phase III, EudraCT No 2012-002814-38

  Top recruiter in Germany

• Randomized double-blind study with JNJ-56021927 versus placebo in combination with Abiraterone in metastatic HPRC in chemotherapy-naive men, ACIS, 56021927PCR3001, phase III, EudraCT No 2014-001718-2

  Top recruiter in Germany

• Pembrolizumab (MK-3475) in subjects with mCRPC previously treated with chemotherapy, KEYNOTE-199, MK-3475-199, phase II, EudraCT 2015-003644-40

  Top recruiter in Germany

• European prospective non-interventional study to evaluate efficacy of enzalutamide in the treatment of patients with metastatic hormone-refractory prostate cancer, PREMISE, 9785-MA-1002, phase IV

  Top recruiter in Germany

• Randomized, open-label study of Cabazitaxel versus an androgen receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent, CARD, LPS14201, Phase IV, EudraCT No 2014-004676-29

  Top recruiter in Germany

• Randomized double-blind study with JNJ-56021927 plus androgen deprivation therapy (ADT) versus ADT in subjects with low volume metastatic, hormone sensitive prostate cancer, TITAN, 56021927PCR3002, phase III, EudraCT No 2015-000735-32

• Abiraterone in Kombination mit neu begonnener LH-RH Therapie beim Hochrisikopatienten mit Prostatakarzinom, LATITUDE, Phase II, EudraCT Nr. 2012-002940-26

  Top recruiter in Germany

• Randomized, double-blind, comparative study of Abiraterone Acetata plus Prednisone plus androgen deprivation therapy (ADT) verus ADT alone in newly diagnosed subjects with high-risk, metastatic hormone-naive prostate cancer (mHNPC), LATITUDE, phase III, EudraCT: 2012-002940-26 33

  Top recruiter in Germany

• Cabozantinib versus Prednisone in metastatic hormonrefractory prostate cancer, COMET-1, XL194-307, phase III, EudraCT No 2012-001834-33

  Top recruiter in Germany

• Treatment with Degarelix versus Goserelin in hormone-naive prostate cancer patients, phase III, EudraCT No 2008-005276-27 

  Top recruiter in Germany

• Open label study with enzalutamide in patients with hormone-refractory prostate cancer having progressed on abiraterone therapy, phase IV, EudraCT No 2 013-002271-17

  2nd top recruiter in world, 1st in Germany

• Randomized double-blind study with PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or mildly symptomatic metastatic, castrate-resistant prostate cancer, phase III, EudraCT No 2 010-021196-85

  2nd top recruiter in Germany

• Randomized double-blind study with RNActive versus placebo in metastasized, chemonaive, hormone refractory prostate cancer patients, phase IIb, EudraCT No 2011-006314-14

  Top recruiter in world

• TAK-700 / Prednisone versus placebo in chemonaive metastatic hormone refractory prostate cancer patients, phase III, EudraCT No 2010-018661-35

  Top recruiter in Germany

• Randomized double-blind study with TAK-700 / Prednisone in metastatic hormone refractory prostate cancer patients who have progressed after doce chemotherapy, phase III, EudraCT No 2010-018662-2

  2nd top recruiter in Germany

• Firstlinetherapy with Doce / Prednisone +/- OGX-011 in metastatic hormone refractory prostate cancer patients, phase III, EudraCT No 2010-021011-16

  2nd top recruiter in world, 1st in Germany

• Abiraterone with different steroid regimens for preventing symptoms associated with mineralocorticoide excess in asymptomatic, chemotherapy-naive and metastatic CRPC, phase II, EudraCT No 2012-004331-23

  3rd top recruiter in world, 1st in Germany

Adresse: http://www.studienurologie.de/referenzen/top-anzahl-betreuter-patienten/ Treffer-Übereinstimmung: 0,01

Adresse: http://www.studienurologie.de/referenzen/auszeichnungen/ Treffer-Übereinstimmung: 0,00